Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.57 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.37 |
| ▸ | GNRHR | P30968 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263564 | 0.84 | NR1H2 (0.40) | RXRANR1H2NR1H3GNRHRKDM4E | |
| SCHEMBL4897287 | 0.83 | KDM4E (0.52) | RXRANR1H2NR1H3KDM4EALDH1A1 | |
| SCHEMBL2387977 | 0.81 | RXRA (0.66) | RXRANR1H2NR1H3PTGS2 | |
| SCHEMBL2262731 | 0.80 | RXRA (0.83) | RXRANR1H2NR1H3MAPK14GNRHR | |
| SCHEMBL12366310 | 0.79 | RXRA (0.59) | RXRANR1H2NR1H3P2RX7MAPK14 | |
| SCHEMBL14214400 | 0.78 | RXRA (0.84) | RXRANR1H2NR1H3P2RX7MAPK14 | |
| SCHEMBL2264665 | 0.76 | NR1H2 (0.51) | RXRANR1H2NR1H3GNRHRHTR2A | |
| SCHEMBL14214340 | 0.75 | RXRA (0.75) | RXRANR1H2NR1H3MAPK14GNRHR | |
| SCHEMBL2389756 | 0.74 | RXRA (0.63) | RXRANR1H2NR1H3PTGS2 | |
| SCHEMBL2390069 | 0.73 | RXRA (0.78) | RXRANR1H2NR1H3MAPK14GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119488-A1 | Modulators Of Nuclear Receptors | EXELIXIS, INC. (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119488-A1 | Modulators Of Nuclear Receptors | NR1H2, NR0B1, NR1H3 | RXRA 20/4885NR1H2 1/4885NR1H3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.